13 slides from Fresenius Se & Co. Kgaa's earnings presentation, Feb 20, 2008
Slide 1: Press conference – 2007 Results
Press conference – 2007 Results February 20, 2008
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Slide 3: Achieving Profitable Growth in Attractive Health Care Segments
Achieving Profitable Growth in Attractive Health Care Segments Fresenius Biotech Oncology and Immunology Therapies Fresenius Fresenius Fresenius Fresenius Medical Care Kabi Helios Vamed Dialysis Equipment Infusion and Nutrition Hospital Operations Engineering and and Services Therapies Services for
Slide 4: Fresenius Group: Strong Financial Results
Fresenius Group: Strong Financial Results €m 11,358 Sales 10,777 +10 % cc 7,889 1,609 EBIT 7,064 7,271 1,444 +17 % cc 5-yrs-CAGR: 13 % 969 781 845 5-yrs-CAGR: 20 % 330 410 Net 168 222 Income 115 +28 % cc 5-yrs-CAGR: 37 % 2003 2004 2005 2006 2007 Press Conference – Results FY 2007, Fresenius SE, Corp
Slide 5: Fresenius Group: Double-Digit EBIT Growth in all Business Segments
Fresenius Group: Double-Digit EBIT Growth in all Business Segments Fresenius Fresenius Fresenius Fresenius FY/2007 Medical Care Kabi Helios Vamed Sales US$ 9,720 m € 2,030 m € 1,841 m € 408 m Growth +14 % +7 % +10 % +4 % EBIT US$ 1,580 m € 332 m € 155 m € 26 m Growth +20 % +14 % +17 % +13 % Press Co
Slide 6: Fresenius Group: ~15 % Dividend Increase Proposed
Fresenius Group: ~15 % Dividend € Increase Proposed € 0.67 0.58 - Proposed dividend: 0.50 € 0.66 per ordinary share 0.46 0.42 € 0.67 per preference share 0.39 0.35 0.32 - 15th consecutive dividend 0.27 increase - Total distribution: € 103.2 m 1999 2000 2001 2002 2003 2004 2005 2006 2007 Proposal Pre
Slide 7: Fresenius Kabi: Accomplishments 2007
Fresenius Kabi: Accomplishments 2007 - Strong organic sales growth and further EBIT margin expansion - 2007 acquisitions with ~€ 130 m annualized sales - Nestlé’s enteral nutrition divestitures in France / Spain - Ribbon, manufacturer of antibiotic agents in Italy - Sanderson, leader in infusion sol
Slide 8: Fresenius Helios: Accomplishments 2007
Fresenius Helios: Accomplishments 2007 - Organic sales growth +3 %, excellent 17 % EBIT increase - Significant acquisition activity - 5 hospitals with ~1,700 beds - ~€ 230 m annualized sales - Fifth maximum-care hospital (Krefeld/Hüls) acquired - New financial reporting system with maximum transpare
Slide 9: Fresenius Vamed: Accomplishments 2007
Fresenius Vamed: Accomplishments 2007 Business Characteristics - Project business – project management, consulting, planning, engineering, contracting – 63 % of sales - Service business – facility management, operations management in selected intl. markets – 37 % of sales - Sales distribution: 59 %
Slide 10: Fresenius Biotech: Anticipated Study / Approval Events and Newsflow
Fresenius Biotech: Anticipated Study / Approval Events and Newsflow H1/08 H2/08 H1/09 H2/09 1 Dec 21, 2007 Filing Expected dossier dispatched to EMEA 4 EMEA/CHMP Opinion Removab malignant ascites Removab malignant ascites 2 Jan 30, 2008 Removab Expected Removab approval malignant File accepted and s
Slide 11: Fresenius Business Segments: Financial Outlook 2008
Fresenius Business Segments: Financial Outlook 2008 Fresenius Kabi Sales growth (cc) 12 – 15 % EBIT margin ~16.5 %* *16.5 – 17.0 % before recent acquisitions Fresenius Helios Sales > € 2,050 m EBIT € 160 – 170 m Fresenius Vamed Sales growth 5 – 10 % EBIT growth 5 – 10 % Fresenius Biotech EBIT ~ € -5
Slide 12: Fresenius Group: Outlook 2008
Fresenius Group: Outlook 2008 Guidance Revenue growth 8 - 10 % in constant currency Net income growth in constant currency 10 - 15 % Capex ~ € 750 m Press Conference – Results FY 2007, Fresenius SE, Corporate Communications © Copyright, February 20, 2008 Page 12
Slide 13: Fresenius Group: Poised for Continued Profitable Growth
Fresenius Group: Poised for Continued Profitable Growth - Leading positions in non-cyclical markets with predictable growth - Industry-leading organic growth in all business segments - Diversified revenue and earnings base - International expansion as key organic growth driver - Excellent acquisitio